MacDougall Biomedical Communications works the PR beat for Enanta Pharmaceuticals, the Massachusetts-based biotech focused on developing drugs to fight hepatitis C and MRSA infections.
Enanta this week filed for an initial public offering aimed to raise as much as $69M.
The number of shares and offering price have not yet been determined.
MacDougall, which specializes in PR for life sciences companies, is based in Wellesley, Mass. Enanta is an eight-year client of the firm. Senior VP Kari Watson leads the work.
Enanta in October entered phase 3 clinical trials for a hepatitis C treatment developed with Abbott Laboratories.